Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 0148

Next Previous
Search
Drug Profile

SP 0148

Alternative Names: ACAM 529; dl5-29 HSV-2 vaccine - Acambis; Herpes-simplex-2-vaccine-Sanofi; Herpes-simplex-vaccine-Sanofi; Herpes-simplex-virus-2-vaccine-Sanofi; Herpes-simplex-virus-vaccine-Sanofi; HSV-2-dl5-29; HSV-2-vaccine-Sanofi; HSV-529; HSV-vaccine-NIAID; HSV-vaccine-Sanofi; SP-0148

Latest Information Update: 03 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard Medical School
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 03 Mar 2023 Discontinued - Phase-I/II for Herpes simplex virus infections (Recurrent) in USA (IM) (Sanofi pipeline, January 2023)
  • 25 Oct 2022 Sanofi terminated its phase I/II trial in Herpes simplex virus infections (Recurrent) in USA (IM) due to business reason (NCT04222985)
  • 05 May 2022 As of May 2022, Sanofi discontinues the development of SP 0148 and terminates the deal with HSV immunotherapy (Sanofi pipeline, May 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top